LTV1

Summary

LTV1 (LTV1 ribosome biogenesis factor, HGNC:21173) is a protein-coding gene on chromosome 6q24.2, encoding Protein LTV1 homolog (Q96GA3). Essential for ribosome biogenesis. It is a selective cancer dependency (DepMap: 89.9% of cell lines).

Predicted to be involved in ribosomal small subunit biogenesis and ribosomal small subunit export from nucleus. Located in cytosol and nucleoplasm. Implicated in inflammatory poikiloderma with hair abnormalities and acral keratoses.

Source: NCBI Gene 84946 — RefSeq curated summary.

At a glance

• Gene–disease (curated): inflammatory poikiloderma with hair abnormalities and acral keratoses (Moderate, GenCC)
• Clinical variants (ClinVar): 78 total — 1 pathogenic
• Phenotypes (HPO): 11
• Druggable target: yes
• Cancer dependency (DepMap): dependent in 89.9% of screened cell lines
• MANE Select transcript: NM_032860

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:21173
Approved symbol	LTV1
Name	LTV1 ribosome biogenesis factor
Location	6q24.2
Locus type	gene with protein product
Status	Approved
Aliases	FLJ14909, dJ468K18.4
Ensembl gene	ENSG00000135521
Ensembl biotype	protein_coding
OMIM	620074
Entrez	84946

Gene structure

Transcript identifiers

Ensembl transcripts: 7 — 7 protein_coding

ENST00000367576, ENST00000868801, ENST00000918498, ENST00000918499, ENST00000918500, ENST00000918501, ENST00000970779

RefSeq mRNA: 2 — MANE Select: NM_032860 NM_001329953, NM_032860

CCDS: CCDS5201

Canonical transcript exons

ENST00000367576 — 11 exons

Exon	Start	End
ENSE00000455901	143862104	143862243
ENSE00000764889	143850131	143850218
ENSE00000764892	143860426	143860553
ENSE00000764894	143862844	143862896
ENSE00000764895	143863086	143863286
ENSE00000799013	143846051	143846224
ENSE00001122515	143857752	143858007
ENSE00001122520	143857303	143857444
ENSE00001445066	143863417	143863812
ENSE00001445069	143843338	143843480
ENSE00003508857	143844486	143844617

Expression profiles

Bgee: expression breadth ubiquitous, 254 present calls, max score 95.82.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 38.5626 / max 486.0804, expressed in 1820 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
70268	37.5638	1818
70267	0.9988	631

Top tissues by expression

256 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
epithelial cell of pancreas	CL:0000083	95.82	gold quality
left ventricle myocardium	UBERON:0006566	91.50	silver quality
gastrocnemius	UBERON:0001388	91.41	gold quality
upper arm skin	UBERON:0004263	91.19	gold quality
kidney epithelium	UBERON:0004819	91.09	silver quality
monocyte	CL:0000576	90.99	gold quality
skin of abdomen	UBERON:0001416	90.97	gold quality
cardiac muscle of right atrium	UBERON:0003379	90.86	silver quality
muscle of leg	UBERON:0001383	90.77	gold quality
leukocyte	CL:0000738	90.62	gold quality
left uterine tube	UBERON:0001303	90.45	gold quality
oocyte	CL:0000023	90.25	gold quality
sperm	CL:0000019	90.23	gold quality
smooth muscle tissue	UBERON:0001135	90.16	gold quality
body of pancreas	UBERON:0001150	90.16	gold quality
skin of leg	UBERON:0001511	89.95	gold quality
myocardium	UBERON:0002349	89.93	silver quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	89.87	gold quality
peritoneum	UBERON:0002358	89.75	gold quality
omental fat pad	UBERON:0010414	89.75	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	89.59	gold quality
zone of skin	UBERON:0000014	89.55	gold quality
deltoid	UBERON:0001476	89.49	gold quality
left adrenal gland	UBERON:0001234	89.45	gold quality
right adrenal gland cortex	UBERON:0035827	89.44	gold quality
islet of Langerhans	UBERON:0000006	89.41	gold quality
pancreas	UBERON:0001264	89.39	gold quality
vermiform appendix	UBERON:0001154	89.30	gold quality
adipose tissue of abdominal region	UBERON:0007808	89.28	gold quality
left adrenal gland cortex	UBERON:0035825	89.25	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	7.59
E-MTAB-7249	no	312.71

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

42 targeting LTV1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-23A-3P	99.95	74.24	3163
HSA-MIR-23B-3P	99.95	74.24	3163
HSA-MIR-23C	99.95	73.92	3192
HSA-MIR-338-5P	99.92	72.34	2951
HSA-MIR-374B-5P	99.90	69.98	2734
HSA-MIR-374A-5P	99.90	71.34	2923
HSA-MIR-106A-5P	99.90	73.94	2683
HSA-MIR-17-5P	99.89	73.83	2665
HSA-MIR-106B-5P	99.88	74.72	2795
HSA-MIR-20A-5P	99.88	74.76	2769
HSA-MIR-20B-5P	99.88	74.01	2621
HSA-MIR-519D-3P	99.88	73.97	2607
HSA-MIR-526B-3P	99.88	74.06	2587
HSA-MIR-93-5P	99.88	73.98	2606
HSA-MIR-369-3P	99.85	70.52	2264
HSA-MIR-374C-5P	99.80	72.06	2910
HSA-MIR-655-3P	99.80	72.19	2909
HSA-MIR-4699-3P	99.71	70.15	3142
HSA-MIR-7154-5P	99.69	70.52	1900
HSA-MIR-4470	99.66	69.35	1767
HSA-MIR-545-5P	99.66	70.18	2308
HSA-MIR-5197-5P	99.64	69.08	1494
HSA-MIR-4328	99.57	71.06	4094
HSA-MIR-3923	99.52	69.21	446
HSA-MIR-21-5P	99.46	70.54	1035
HSA-MIR-16-2-3P	99.29	70.60	1954

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 89.9% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 2)

• Ribosome biogenesis factor Ltv1 chaperones the assembly of the small subunit head. (PMID:30348748)
• Mutations in the ribosome biogenesis factor gene LTV1 are linked to LIPHAK syndrome, a novel poikiloderma-like disorder. (PMID:34999892)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	ltv1	ENSDARG00000008490
mus_musculus	Ltv1	ENSMUSG00000019814
rattus_norvegicus	Ltv1	ENSRNOG00000015217
drosophila_melanogaster	LTV1	FBGN0027525
caenorhabditis_elegans	T23D8.3	WBGENE00011944

Protein

Protein identifiers

Protein LTV1 homolog — Q96GA3 (reviewed: Q96GA3)

All UniProt accessions (1): Q96GA3

UniProt curated annotations — full annotation on UniProt →

Function. Essential for ribosome biogenesis.

Subcellular location. Cytoplasm.

Tissue specificity. Expressed in the epidermis.

Disease relevance. Inflammatory poikiloderma with hair abnormalities and acral keratoses (IPHAK) [MIM:620199] An autosomal recessive disorder characterized by mottled hyper- and hypopigmentation of the skin, sparse scalp hair and eyelashes, sparse or absent eyebrows, and palmoplantar keratoses. The disease may be caused by variants affecting the gene represented in this entry.

Similarity. Belongs to the LTV1 family.

RefSeq proteins (2): NP_001316882, NP_116249* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR007307	Ltv1	Family

Pfam: PF04180

UniProt features (22 total): modified residue 5, region of interest 4, helix 4, strand 3, compositionally biased region 2, chain 1, sequence variant 1, turn 1, coiled-coil region 1

Structure

Experimental structures (PDB)

13 structures.

PDB	Method	Resolution (Å)
7WTU	ELECTRON MICROSCOPY	3
7WTZ	ELECTRON MICROSCOPY	3
7WTT	ELECTRON MICROSCOPY	3.1
7WTX	ELECTRON MICROSCOPY	3.1
7WTW	ELECTRON MICROSCOPY	3.2
7WU0	ELECTRON MICROSCOPY	3.3
6G18	ELECTRON MICROSCOPY	3.6
8ZDD	ELECTRON MICROSCOPY	3.7
8ZDC	ELECTRON MICROSCOPY	3.8
6G4S	ELECTRON MICROSCOPY	4
6G51	ELECTRON MICROSCOPY	4.1
6G4W	ELECTRON MICROSCOPY	4.5
6G53	ELECTRON MICROSCOPY	4.5

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96GA3-F1	69.24	0.09

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (5): 248, 331, 408, 17, 24

Function

Pathways and Gene Ontology

Reactome pathways

4 pathways

ID	Pathway
R-HSA-6791226	Major pathway of rRNA processing in the nucleolus and cytosol
R-HSA-72312	rRNA processing
R-HSA-8868773	rRNA processing in the nucleus and cytosol
R-HSA-8953854	Metabolism of RNA

MSigDB gene sets: 164 (showing top): GOBP_RIBOSOME_BIOGENESIS, GOBP_NUCLEAR_TRANSPORT, GOBP_RIBOSOMAL_SMALL_SUBUNIT_BIOGENESIS, DODD_NASOPHARYNGEAL_CARCINOMA_UP, GOBP_NUCLEAR_EXPORT, MODULE_207, GOBP_ORGANELLE_LOCALIZATION, GOBP_RIBONUCLEOPROTEIN_COMPLEX_BIOGENESIS, REACTOME_METABOLISM_OF_RNA, GOCC_PRERIBOSOME, GOCC_RIBONUCLEOPROTEIN_COMPLEX, SCGGAAGY_ELK1_02, YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_11, KRIGE_RESPONSE_TO_TOSEDOSTAT_6HR_DN, GOBP_RIBOSOMAL_SMALL_SUBUNIT_EXPORT_FROM_NUCLEUS

GO Biological Process (3): ribosomal small subunit export from nucleus (GO:0000056), ribosome biogenesis (GO:0042254), ribosomal small subunit biogenesis (GO:0042274)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (5): nucleus (GO:0005634), nucleoplasm (GO:0005654), cytosol (GO:0005829), preribosome, small subunit precursor (GO:0030688), cytoplasm (GO:0005737)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
rRNA processing in the nucleus and cytosol	1
Metabolism of RNA	1
rRNA processing	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
ribonucleoprotein complex biogenesis	2
ribosomal subunit export from nucleus	1
ribosome biogenesis	1
binding	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
cytoplasm	1
preribosome	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

2668 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
LTV1	BYSL	Q13895	991
LTV1	RIOK2	Q9BVS4	943
LTV1	TSR1	Q2NL82	943
LTV1	PNO1	Q9NRX1	916
LTV1	RRAGC	Q9HB90	894
LTV1	NOB1	Q9ULX3	889
LTV1	RPS3	P23396	838
LTV1	XPO1	O14980	823
LTV1	RRP12	Q5JTH9	795
LTV1	RPS10	P46783	779
LTV1	RIOK1	Q9BRS2	776
LTV1	NMD3	Q96D46	725
LTV1	RPS20	P17075	690
LTV1	TXNL4B	Q9NX01	678
LTV1	GPATCH2	Q9NW75	637

IntAct

182 interactions, top by confidence:

A	B	Type	Score
BMI1	CBX4	psi-mi:“MI:0914”(association)	0.900
BYSL	LTV1	psi-mi:“MI:0915”(physical association)	0.870
LTV1	BYSL	psi-mi:“MI:0915”(physical association)	0.870
PCGF2	CBX4	psi-mi:“MI:0914”(association)	0.840
RPS3	LTV1	psi-mi:“MI:0915”(physical association)	0.800
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
BYSL	PARN	psi-mi:“MI:0914”(association)	0.640
TSR1	RPS3	psi-mi:“MI:0914”(association)	0.640
LIN28A	IGF2BP3	psi-mi:“MI:0914”(association)	0.640
RACK1	RIOK3	psi-mi:“MI:0914”(association)	0.640
LTV1	CSNK2A1	psi-mi:“MI:0217”(phosphorylation reaction)	0.590
GAS2L2	LTV1	psi-mi:“MI:0915”(physical association)	0.560
RPS14	MAGEB2	psi-mi:“MI:0914”(association)	0.560
ZNF324B	ZNF316	psi-mi:“MI:0914”(association)	0.530
RPS2	MPHOSPH10	psi-mi:“MI:0914”(association)	0.530
ZBTB48	ZBTB24	psi-mi:“MI:0914”(association)	0.530
TSR1	PARN	psi-mi:“MI:0914”(association)	0.530
CBX6	IGF2BP3	psi-mi:“MI:0914”(association)	0.530
RIOK2	BYSL	psi-mi:“MI:0914”(association)	0.530
RPS3	ZNF316	psi-mi:“MI:0914”(association)	0.530

BioGRID (260): LTV1 (Two-hybrid), LTV1 (Affinity Capture-MS), LTV1 (Affinity Capture-MS), LTV1 (Affinity Capture-MS), LTV1 (Affinity Capture-MS), LTV1 (Affinity Capture-MS), LTV1 (Co-fractionation), LTV1 (Affinity Capture-MS), LTV1 (Reconstituted Complex), LTV1 (Proximity Label-MS), LTV1 (Proximity Label-MS), LTV1 (Proximity Label-MS), LTV1 (Proximity Label-MS), LTV1 (Proximity Label-MS), LTV1 (Proximity Label-MS)

ESM2 similar proteins: A4IGY3, A7SD85, A9ULY7, B0W6N3, C8VBH3, O08837, O57476, P0CO94, P0CO95, P39964, P51951, P92948, Q0VC06, Q13435, Q16543, Q173M7, Q28HX4, Q2KJC1, Q3TQI7, Q3UJB0, Q4P652, Q4R6Y7, Q4V838, Q4WHG0, Q4WVH3, Q51LS1, Q52G60, Q5EAC6, Q5H7N8, Q5R8B2, Q5RC87, Q5ZKI4, Q5ZKM1, Q61081, Q63692, Q6A068, Q6AYJ5, Q6DD06, Q7JWR9, Q7K3D8

Diamond homologs: Q0VC06, Q4V838, Q5R8B2, Q5U3J8, Q68FR7, Q6NSQ7, Q7KN79, Q8T1D4, Q96GA3, Q10191

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 188 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Eukaryotic Translation Initiation	14	33.5×	1e-16
Cap-dependent Translation Initiation	14	33.5×	1e-16
SARS-CoV-1 modulates host translation machinery	14	33.5×	1e-16
Eukaryotic Translation Elongation	14	30.2×	3e-16
Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S	14	29.5×	4e-16
Nonsense-Mediated Decay (NMD)	15	27.1×	2e-16
Influenza Viral RNA Transcription and Replication	15	25.1×	4e-16
SARS-CoV-2 modulates host translation machinery	14	24.3×	6e-15

GO biological processes:

GO term	Partners	Fold	FDR
maturation of SSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA)	7	28.4×	7e-07
maturation of SSU-rRNA	6	27.7×	9e-06
cytoplasmic translation	19	21.2×	3e-17
ribosomal small subunit biogenesis	15	20.6×	2e-13
stress granule assembly	5	18.1×	6e-04
mRNA stabilization	6	13.2×	5e-04
translation	20	12.4×	9e-14
negative regulation of proteasomal ubiquitin-dependent protein catabolic process	5	12.1×	4e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

78 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	58
Likely benign	2
Benign	3

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
2443758	NM_032860.5(LTV1):c.503A>G (p.Asn168Ser)	Pathogenic

SpliceAI

2203 predictions. Top by Δscore:

Variant	Effect	Δscore
6:143844577:A:G	donor_gain	1.0000
6:143844618:G:GG	donor_gain	1.0000
6:143846049:A:AG	acceptor_gain	1.0000
6:143846050:G:GG	acceptor_gain	1.0000
6:143846050:GATA:G	acceptor_gain	1.0000
6:143846192:A:T	donor_gain	1.0000
6:143846224:AGTAA:A	donor_loss	1.0000
6:143846225:G:GG	donor_gain	1.0000
6:143846225:GT:G	donor_loss	1.0000
6:143846226:T:G	donor_loss	1.0000
6:143850128:A:AG	acceptor_gain	1.0000
6:143850129:A:G	acceptor_gain	1.0000
6:143850130:GA:G	acceptor_gain	1.0000
6:143857297:TTCTA:T	acceptor_loss	1.0000
6:143857298:TCTA:T	acceptor_loss	1.0000
6:143857299:CTA:C	acceptor_loss	1.0000
6:143857301:A:AC	acceptor_loss	1.0000
6:143857301:A:AG	acceptor_gain	1.0000
6:143857301:AG:A	acceptor_gain	1.0000
6:143857302:G:GT	acceptor_gain	1.0000
6:143857302:GG:G	acceptor_gain	1.0000
6:143857386:G:GT	donor_gain	1.0000
6:143857404:GCCAA:G	donor_gain	1.0000
6:143857421:A:T	donor_gain	1.0000
6:143857425:G:GT	donor_gain	1.0000
6:143857432:G:T	donor_gain	1.0000
6:143857445:G:GG	donor_gain	1.0000
6:143858004:GAAG:G	donor_gain	1.0000
6:143858006:AGGTA:A	donor_loss	1.0000
6:143858007:GGT:G	donor_loss	1.0000

AlphaMissense

3173 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
6:143844534:T:C	F18L	0.998
6:143844536:T:A	F18L	0.998
6:143844536:T:G	F18L	0.998
6:143844535:T:C	F18S	0.997
6:143844549:C:G	R23G	0.997
6:143844550:G:C	R23P	0.997
6:143844562:A:G	D27G	0.996
6:143844598:T:A	V39D	0.996
6:143844601:T:C	L40P	0.996
6:143844601:T:A	L40Q	0.995
6:143846130:T:C	L72P	0.995
6:143850147:T:C	L109S	0.995
6:143857338:G:C	A145P	0.995
6:143844561:G:C	D27H	0.994
6:143857342:T:C	L146P	0.994
6:143863421:G:C	R441P	0.994
6:143844552:A:C	S24R	0.993
6:143844554:C:A	S24R	0.993
6:143844554:C:G	S24R	0.993
6:143844563:T:A	D27E	0.993
6:143844563:T:G	D27E	0.993
6:143857335:G:C	A144P	0.993
6:143844544:T:A	V21D	0.992
6:143844562:A:C	D27A	0.992
6:143844562:A:T	D27V	0.992
6:143862234:T:C	S352P	0.992
6:143863282:G:C	R438P	0.992
6:143844559:G:C	R26P	0.991
6:143850195:T:C	L125S	0.991
6:143862243:A:C	S355R	0.990

dbSNP variants (sampled 300 via entrez): RS1000147197 (6:143843943 T>G), RS1000175575 (6:143847849 CT>C,CTT), RS1000298555 (6:143847607 T>C,G), RS1000365730 (6:143849507 T>C), RS1000450271 (6:143842021 C>G), RS1000498357 (6:143842947 A>T), RS1000501873 (6:143842661 G>A,C), RS1000637476 (6:143853741 C>A,G,T), RS1000757631 (6:143859895 G>A), RS1000813219 (6:143848489 C>T), RS1000852959 (6:143854720 G>C), RS1001037633 (6:143861233 T>C,G), RS1001141294 (6:143860997 G>C), RS1001202373 (6:143857038 G>A,T), RS1001357334 (6:143851007 T>G)

Disease associations

OMIM: gene MIM:620074 | disease phenotypes: MIM:620199

GenCC curated gene-disease

Disease	Classification	Inheritance
inflammatory poikiloderma with hair abnormalities and acral keratoses	Moderate	Autosomal recessive

Mondo (1): inflammatory poikiloderma with hair abnormalities and acral keratoses (MONDO:0859355)

Orphanet (0):

HPO phenotypes

11 total (11 of 11 shown, HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0000653	Sparse eyelashes
HP:0001029	Poikiloderma
HP:0001070	Mottled pigmentation
HP:0002209	Sparse scalp hair
HP:0002223	Absent eyebrow
HP:0003593	Infantile onset
HP:0011463	Childhood onset
HP:0034572	Pigment incontinence
HP:0045075	Sparse eyebrow
HP:0200016	Acrokeratosis

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4742314 (PROTEIN-PROTEIN INTERACTION)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

36 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	affects cotreatment, increases abundance, increases expression, decreases expression	3
bisphenol A	affects expression, affects cotreatment, increases methylation	2
aristolochic acid I	decreases expression	1
FR900359	decreases phosphorylation	1
dicrotophos	decreases expression	1
pirinixic acid	affects binding, increases activity, increases expression	1
glycidyl methacrylate	increases expression	1
manganese chloride	affects cotreatment, increases abundance, increases expression	1
coumarin	affects phosphorylation	1
cyclic 3’,5’-uridine monophosphate	affects binding	1
CGP 52608	affects binding, increases reaction	1
(+)-JQ1 compound	decreases expression	1
Irinotecan	decreases expression	1
Fulvestrant	increases methylation, affects cotreatment	1
Arsenic	affects cotreatment, increases abundance, increases expression	1
Atrazine	decreases expression	1
Caffeine	affects phosphorylation	1
Dichlorodiphenyl Dichloroethylene	increases expression	1
Doxorubicin	decreases expression	1
Enzyme Inhibitors	decreases activity, increases O-linked glycosylation	1
Estradiol	increases expression	1
Ethyl Methanesulfonate	decreases expression	1
Formaldehyde	decreases expression	1
Hydrogen Peroxide	affects expression	1
Lead	affects expression	1
Manganese	increases abundance, increases expression, affects cotreatment	1
Methyl Methanesulfonate	decreases expression	1
Ribonucleotides	affects binding	1
Smoke	decreases expression	1
Tobacco Smoke Pollution	increases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4713767	Binding	Protac activity at CRBN/LTV1 in human BxPC-3 cells assessed as LTV1 degradation incubated for 16 hrs by proteomic analysis	Discovery of a Napabucasin PROTAC as an Effective Degrader of the E3 Ligase ZFP91. — J Med Chem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.